Coronavirus Strategies to Boost Community Coronavirus Strategies to Boost Community

ADVERTISEMENT

Oncology Dietitian Exposes Fraud in CDC’s HPV Vaccine Effectiveness Study

HPV Vaccine

Story at-a-glance -

  • An oncology dietitian has pointed out significant discrepancies in a new HPV vaccine effectiveness study that claims the vaccine’s effectiveness is “high”
  • Recent reductions in HPV infection prevalence among young women in the US cannot be said to be due to introduction of Gardasil vaccine in 2006 and use of HPV vaccines by pre-teen and teenage girls since then; the data clearly shows that unvaccinated girls had the best outcome
  • In 2007-2010, HPV prevalence dropped 27.3 percent in the unvaccinated girls, but only declined by 5.8 percent in the vaccinated group. In four out of five different measures, the unvaccinated girls had a lower incidence of HPV
  • According to Merck’s own research before Gardasil was licensed, if you've been exposed to HPV strains 16 or 18 prior to receiving Gardasil vaccine, you could increase your risk of precancerous lesions by 44.6 percent.
  • Judicial Watch has received previously withheld documents from the DDHS, which reveal that the National Vaccine Injury Compensation Program has awarded $5,877,710 to 49 victims for harm resulting from the HPV vaccine

By Dr. Mercola

There are currently two HPV vaccines on the market, but if there was any regard for sound scientific evidence, neither would be promoted as heavily as they are. The first, Gardasil, was licensed by the US Food and Drug Administration (FDA) in 2006. It is now recommended as a routine vaccination for girls and women between the ages of 9-26 in the US.


Read the Full Article for Free!
Subscribe to the #1 Natural Health Newsletter
  • Unlock censored health information that Google doesn't want you to read
  • Keep your privacy secure — We are no longer active on Facebook and are blocking our content from Google search to ensure your privacy stays protected
  • Get access to all of Dr. Mercola's health articles, E-books and special reports

Existing Subscribers: Enter your email address for instant access